Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression in the phase Ib/II FORT-2 study.

Authors

Jonathan E. Rosenberg

Department of Medicine, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY

Jonathan E. Rosenberg , Pablo Gajate , Rafael Morales-Barrera , Jae-Lyun Lee , Andrea Necchi , Nicolas Penel , Vittorina Zagonel , Mitchell Robert Sierecki , Weichao Bao , Yinghui Zhou , Peter Ellinghaus , Randy F. Sweis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression.

First Author: Jonathan E. Rosenberg

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

AUREA study: Atezolizumab (Atezo) combined with split-dose gemcitabine plus cisplatin (s-GC) in locally advanced or metastatic urothelial cancer (LA/mUC): A SOGUG study.

First Author: Alfonso Gomez De Liano Lista

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

Avelumab as single agent for patients with metastatic or locally advanced urothelial cancer PD-L1+ unfit for cisplatin: The ARIES study.

First Author: Roberto Iacovelli

insert_chart_outlined

Poster

2020 Genitourinary Cancers Symposium

bookmark_border

PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC).

First Author: Robert A. Huddart